loading
前日終値:
$10.73
開ける:
$10.65
24時間の取引高:
1.03M
Relative Volume:
0.24
時価総額:
$2.30B
収益:
$503.49M
当期純損益:
$-53.47M
株価収益率:
-42.37
EPS:
-0.26
ネットキャッシュフロー:
$-26.89M
1週間 パフォーマンス:
+2.11%
1か月 パフォーマンス:
+23.38%
6か月 パフォーマンス:
+53.24%
1年 パフォーマンス:
+62.27%
1日の値動き範囲:
Value
$10.51
$11.03
1週間の範囲:
Value
$10.46
$11.15
52週間の値動き範囲:
Value
$5.92
$11.15

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Name
名前
Biocryst Pharmaceuticals Inc
Name
セクター
Healthcare (1170)
Name
電話
919-859-1302
Name
住所
4505 EMPEROR BOULEVARD, DURHAM, NC
Name
職員
580
Name
Twitter
@biocrystpharma
Name
次回の収益日
2025-02-24
Name
最新のSEC提出書
Name
BCRX's Discussions on Twitter

BCRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
BCRX
Biocryst Pharmaceuticals Inc
11.02 2.26B 503.49M -53.47M -26.89M -0.26
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.13 50.54B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
171.41 74.02B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.86 4.22M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.97 45.82B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.33 20.31B 16.54B -1.64B 749.00M -1.45

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-29 開始されました Cantor Fitzgerald Overweight
2025-02-25 開始されました Wedbush Outperform
2023-11-20 再開されました JP Morgan Overweight
2023-09-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2023-08-04 アップグレード Jefferies Hold → Buy
2023-07-13 アップグレード BofA Securities Neutral → Buy
2023-02-22 アップグレード Needham Hold → Buy
2022-11-02 アップグレード Evercore ISI In-line → Outperform
2022-08-05 ダウングレード Evercore ISI Outperform → In-line
2022-08-05 ダウングレード Oppenheimer Outperform → Perform
2022-04-18 ダウングレード Barclays Overweight → Equal Weight
2022-04-11 ダウングレード BofA Securities Buy → Neutral
2021-12-10 開始されました Oppenheimer Outperform
2021-08-06 ダウングレード Jefferies Buy → Hold
2021-08-03 開始されました Cantor Fitzgerald Overweight
2021-03-01 開始されました Cowen Outperform
2020-09-29 再開されました JP Morgan Overweight
2020-06-17 開始されました BTIG Research Neutral
2020-05-05 アップグレード Barclays Equal Weight → Overweight
2019-11-15 アップグレード BofA/Merrill Neutral → Buy
2019-05-24 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2018-11-16 再開されました Piper Jaffray Overweight
2018-08-08 再開されました JP Morgan Overweight
2018-07-17 アップグレード BofA/Merrill Underperform → Neutral
2018-06-22 開始されました Seaport Global Securities Neutral
2018-01-02 アップグレード RBC Capital Mkts Sector Perform → Outperform
2017-12-20 開始されました Barclays Equal Weight
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-09-06 アップグレード JP Morgan Neutral → Overweight
2017-09-06 アップグレード Jefferies Hold → Buy
2017-02-16 開始されました Ladenburg Thalmann Buy
2016-08-12 アップグレード Piper Jaffray Neutral → Overweight
2016-08-04 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 繰り返されました FBR Capital Outperform
2016-02-09 ダウングレード JP Morgan Overweight → Neutral
2016-02-09 ダウングレード Needham Buy → Hold
すべてを表示

Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース

pulisher
07:30 AM

BioCryst (BCRX) Awards Restricted Stock Units to New Employees | BCRX Stock News - GuruFocus

07:30 AM
pulisher
07:17 AM

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BCRX Stock News - GuruFocus

07:17 AM
pulisher
07:01 AM

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

07:01 AM
pulisher
07:00 AM

BioCryst Expands Team with 7 Strategic Hires, Grants 47,250 Restricted Stock Units - Stock Titan

07:00 AM
pulisher
12:59 PM

BioCryst stock soars to 52-week high, hits $11.14 - Investing.com India

12:59 PM
pulisher
Jun 02, 2025

BioCryst stock soars to 52-week high, hits $11.14 By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

BioCryst to Present New Data at 2025 Meeting of the European Aca - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewswire Inc.

Jun 02, 2025
pulisher
May 30, 2025

BioCryst (BCRX) Highlights Positive Data on Berotralstat for HAE Treatment | BCRX Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotrals - GuruFocus

May 30, 2025
pulisher
May 30, 2025

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages | BCRX Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

BioCryst reports efficacy of HAE drug across age groups - Investing.com

May 30, 2025
pulisher
May 30, 2025

BioCryst Highlights Real-world Data Showing ORLADEYO® - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

BCRXBiocryst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan

May 30, 2025
pulisher
May 28, 2025

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year? - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Drugmaker targets younger patients as revenue balloons - The Business Journals

May 28, 2025
pulisher
May 28, 2025

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

May 28, 2025
pulisher
May 27, 2025

BioCryst to Present at Upcoming Investor Conferences | BCRX Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

BioCryst to Present at Upcoming Investor Conferences - The Manila Times

May 27, 2025
pulisher
May 27, 2025

How To Trade (BCRX) - news.stocktradersdaily.com

May 27, 2025
pulisher
May 27, 2025

Bank of America Corp DE Sells 261,127 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 27, 2025
pulisher
May 26, 2025

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade - Yahoo Finance

May 26, 2025
pulisher
May 23, 2025

BioCryst Pharmaceuticals Inc (BCRX) Trading 3.62% Higher on May 22 - GuruFocus

May 23, 2025
pulisher
May 22, 2025

Orladeyo reduces swelling rates in severe HAE: Real-world data - Angioedema News

May 22, 2025
pulisher
May 22, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded by StockNews.com to Strong-Buy Rating - Defense World

May 22, 2025
pulisher
May 21, 2025

Transcript : BioCryst Pharmaceuticals, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

D. E. Shaw & Co. Inc. Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 21, 2025
pulisher
May 20, 2025

BioCryst's Orladeyo up for FDA review in pediatric HAE patients - MSN

May 20, 2025
pulisher
May 20, 2025

BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid Orladeyo success, pipeline progress - Investing.com Nigeria

May 20, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 19, 2025
pulisher
May 19, 2025

Ameriprise Financial Inc. Sells 51,920 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 19, 2025
pulisher
May 18, 2025

Best Momentum Stocks to Buy for May 9th - The Globe and Mail

May 18, 2025
pulisher
May 17, 2025

BioCryst reports ORLADEYO reduces severe HAE attack rates By Investing.com - Investing.com Nigeria

May 17, 2025
pulisher
May 17, 2025

BioCryst Pharmaceuticals (NASDAQ:BCRX) Cut to Buy at StockNews.com - Defense World

May 17, 2025
pulisher
May 16, 2025

(BCRX) Long Term Investment Analysis - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

BioCryst reports ORLADEYO reduces severe HAE attack rates - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

BioCryst Presents New Real-world Evidence Showing Significant an - GuruFocus

May 16, 2025
pulisher
May 16, 2025

BioCryst (BCRX) Highlights Significant HAE Attack Reductions with ORLADEYO | BCRX Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat) - GlobeNewswire

May 16, 2025
pulisher
May 16, 2025

New Clinical Evidence: ORLADEYO Dramatically Reduces HAE Attacks in Both Teens and Severe Patients - Stock Titan

May 16, 2025
pulisher
May 15, 2025

FDA to review Orladeyo application for young children with HAE - Angioedema News

May 15, 2025
pulisher
May 15, 2025

FDA awards BioCryst’s Orladeyo NDA for paediatric HAE - Yahoo

May 15, 2025
pulisher
May 15, 2025

The Manufacturers Life Insurance Company Sells 195,621 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World

May 15, 2025
pulisher
May 14, 2025

BioCryst (BCRX) Gains FDA Priority Review for Pediatric ORLADEYO - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Clearside's Wet AMD Drug Advances to Phase 3: FDA Green Light Could Transform Eye Disease Treatment - Stock Titan

May 14, 2025
pulisher
May 14, 2025

FDA accepts NDA for berotralstat in HAE patients aged 2 to 11 years - Contemporary Pediatrics

May 14, 2025
pulisher
May 14, 2025

INZ-701 shows early promise in treating ENPP1 Deficiency in pediatric patients - Contemporary Pediatrics

May 14, 2025
pulisher
May 14, 2025

BioCryst’s ORLADEYO Receives FDA Priority Review - TipRanks

May 14, 2025
pulisher
May 14, 2025

Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® - GlobeNewswire

May 14, 2025

Biocryst Pharmaceuticals Inc (BCRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$8.425
price down icon 3.28%
drug_manufacturers_specialty_generic RDY
$14.62
price down icon 0.81%
$124.86
price down icon 0.01%
drug_manufacturers_specialty_generic HCM
$14.21
price up icon 2.99%
$324.39
price down icon 0.70%
$17.29
price up icon 0.03%
大文字化:     |  ボリューム (24 時間):